Novartis: it's an uphill climb to the bottom
Healthcare European Pharmaceuticals
Novartis It's an uphill climb to the bottom
from Equal Weight
Earnings and execution headaches:
With the sector at a 30% premium to the EU
market (1yr fwd PE) earnings and execution uncertainties are not en vogue, which is why we now rate Novartis a relative UW (was EW). The company's top-line growth is
>50% dependent on two launch products (Entresto in heart failure and Cosentyx in
lowered -6% from CHF 90.00
psoriasis), which both need to deliver on current expectations to justify today's
valuation - failure would push the ‘15-20 EPS CAGR below sector average exposing
17% of ‘20 EPS and remove CHF9/share in valuation. With Alcon (second largest
division) potentially declining in ‘16 we see little reason for the stock to shed its
discount as earnings and growth trajectory are at risk; there isn't enough pipeline news
flow to protect the multiple. UW rating, PT CHF85 from CHF90 (due to poorer Alcon
outlook and slower Entresto ramp).
Market Cap (CHF mn)
Cosentyx and Entresto are estimated (company provided
Shares Outstanding (mn)
consensus) to deliver a combined $1.5bn in sales in ‘16. Our proprietary data suggests
that is a tough ask. We are optimistic on Cosentyx but less on the Entresto uptake as
52 Wk Avg Daily Volume (mn)
even amongst specialists the new written prescription share remains low. Unfortunately
52 Wk Avg Daily Value (CHF mn)
before Medicare blocks are removed standard prescription trends remain a poor tracker
Dividend Yield (%)
of performance but worryingly Corlanor prescriptions (also HF) are showing no signs of
Return on Equity TTM (%)
inflection following the removal of NDC blocks. Should the same hold true for Entresto
Current BVPS (USD)
in the next few weeks questions will start concerning whether consensus estimates
Source: Thomson Reuters
looking for $5bn in revenues in 2020 are reasonable. Halving the Entresto sales
estimate removes 17% from ‘20 earnings and exposes CHF9/share in valuation.
Alcon's innovation challenges and overall growth malaise now seems
well understood but despite management's promise of a ‘growth acceleration plan'
announced with FY15 results there is no obvious quick fix in our view. Asset disposals
that are earnings dilutive but margin and growth enhancing are not obvious and there
seems little choice but to sit it out. Moving Alcon pharma into Novartis pharma is
clearly an option but can do little in light of the exclusivity losses that face $300m of
Alcon US pharma sales in 2016 alone.
Valuation and risk:
We value Novartis through a DCF valuation, assuming a risk-free
rate derived from the yield curve, an equity risk premium of 5%, an asset beta of 0.9,
pre-tax cost of debt based on CDS spreads and a target debt ratio of 10%. These
assumptions result in a dynamic cost of capital and our price target of CHF85.
NOVN.VX: Financial and Valuation Metrics EPS USD
+44 (0)20 3134 3039
4.99A 5.19A 5.06E 5.34E 5.80E
4.99A 5.19A 5.00E 5.32E 6.17E
5.01A 5.14A 5.09E 5.31E 5.99E
+44 (0)20 3134 7189
16.4 15.8 16.2 15.4 14.2
Source: Barclays Research.
Consensus numbers are from Thomson Reuters
+44 (0)20 3555 2669
Barclays Capital Inc. and/or one of its affiliates does and seeks to do business with companies
covered in its research reports. As a result, investors should be aware that the firm may have a
conflict of interest that could affect the objectivity of this report.
Investors should consider this report as only a single factor in making their investment decision.
+44 (0)20 3134 5995
This research report has been prepared in whole or in part by equity research analysts based outside the US who are not registered/qualified as research analysts with FINRA.
PLEASE SEE ANALYST CERTIFICATION(S) AND IMPORTANT DISCLOSURES BEGINNING ON PAGE 16.
Industry View: NEUTRAL
Stock Rating: UNDERWEIGHT
Income statement ($mn)
2014A 2015E 2016E
CAGR Price (13-Jan-2016)
Following a drastic portfolio
ructuring the company had been on track for a
oothed earnings profile. However the recent
weakness in Alcon and the heavy reliance on Entresto
Pre-tax income (adj)
2.9% and Cosentyx to deliver growth and margin exposes
Net income (adj)
2.4% 2016 earnings estimates as well as the growth
trajectory to risk.
Diluted shares (mn)
The upside to our investment case resides mainly
Margin and return data
with restructuring where every $1bn in savings would
Gross margin (%)
e. A $3bn savings program would add
EBIT (adj) margin (%)
ur margin estimate, driving the upside
Pre-tax (adj) margin (%)
Net (adj) margin (%)
our investment case resides with an
inability to protect the gross margin as Gleevec goes
Balance sheet and cash flow ($mn)
off patent (CHF6/share) as well as Entresto
commercial failure in heart failure (CHF18/share).
Tangible fixed assets
Residual downside resides with further Lucentis
Intangible fixed assets
Cash and equivalents
125,387 121,755 122,196
-0.4% Upside/Downside scenarios
Short and long-term debt
Other long-term liabilities
Total invested capital
Change in working capital
Cash flow from operations
Valuation and leverage metrics
EV/EBITDA (adj) (x)
Equity FCF yield (%)
Dividend yield (%)
Total debt/capital (%)
Net debt/equity (%)
Selected operating metrics
Source: Company data, Barclays Research Note: FY End Dec
Novartis has de-rated over the last three months on the back of two main reasons in our view – continuing weak Alcon performance and a slower than hoped for (by the bulls) initial uptake of Entresto (Novartis' main pipeline/launch product) in heart failure. The stock has pulled back to below its 4 year average relative to the sector and we think it will struggle shed this discount as uncertainty about the growth outlook will unlikely subside anytime soon. The answer to the question ‘has the valuation reached interesting levels' is a clear ‘no' from our perspective.
FIGURE 1 Novartis has de-rates and given top-line exposure recovery seems unlikely
PE (x) rel to sector,
Source: Thompson DataStream, Barclays Research
Despite the promised Alcon ‘growth acceleration plan' (due with FY 2015 late January) there is unlikely going to be a quick fix for the division and with >50% of 2015-20 top-line growth coming from only two products (Entresto in heart failure and Cosentyx in psoriasis) the ongoing lack of visibility especially for Entresto is going to be a major issue for the multiple in our view.
FIGURE 2 Novartis top-line growth is heavily dependent on Entresto and Cosentyx
Source: Barclays Research
The problem is that with the Gleevec US erosion unavoidable from February and Alcon facing headwinds that are not going to be fixed on the quick the company may be forced
into investing less into the launches than hoped in 2016. In turn that means the launch trajectory may stay sub-optimal for now and if our assumption about heart failure guidelines is correct (we think it is unlikely that generic ACE inhibitors will be removed from guidelines which means tough pre-authorisation requirements are here to stay) there may be little evidence to boost confidence in the $5bn consensus (company provided) peak sales estimate for Entresto. For illustrative purposes should Entresto only reach half the estimated sales potential Novartis' EPS CAGR drops to 5% and below the sector average resulting in a PEG of almost 3x, which would screen expensive v the sector – in this scenario 2020 EPS estimates would fall 17%. This sort of execution risk we believe will hold the stock back in the absence of meaningful news flow in 2016 which is why we rate Novartis a relative UW (from EW).
FIGURE 3 Under scenario where Entresto reaches 50% of current estimates the stock is expensive
($m, except per share data)
36 350 1000 2000 3000 4000
100 850 1,750 2,900 4,000 4,950
5.06 5.34 5.80 6.67 7.25 7.35 8%
5.11 5.31 6.06 7.06 7.57 7.92 9%
Basic EPS Scenario 50% Entresto
% below consensus
-1% -7% -11%
Source: Barclays Research, Company provided consensus
Entresto – we have three problems (market potential isn't one)
As mentioned above Novartis' top-line is heavily dependent on Entresto. Confidence in the product's performance will remain a significant contributor to the stock's multiple. IMS prescription trends remain a poor tool to track the product's outlook at the moment as 65% of the product's potential patient population is treated by Medicare and 10% by Medicaid, which means reimbursement blocks (NDC blocks) deny reimbursement in the first six months for the majority of patients before things start to normalise. This at least has been the excuse why prescription trends have been slow. For illustrative purposes assuming that the current US launch trajectory continues in a linear manner, IMS prescription data projects US Entresto revenues of c$350m in 2020E.
It is thought that the launch trajectory will pick-up
a) once Medicare/Medicaid reimbursement is achieved, and
b) after ACC/AHA guideline recommendation for Entresto in 2016.
Unfortunately there has been no inflection for Amgen's Corlanor (also heart failure) which has worked through the majority of the National Drug Code (NDC) blocks and a Class1A/Class1B guideline recommendation for Entresto is unlikely to displace the Class1A recommendation for ACE inhibitors in symptomatic heart failure. It seems that at the moment pharmacy benefit managers (PBMs) have put tough pre-authorisation restrictions in place for Entresto (including prior failure on ACE inhibitors), which we believe will continue to dampen uptake especially in the primary care prescriber base which accounts for just under half of total written prescriptions. We would not be surprised to see Novartis management talk down the Entresto uptake in H1 2016 arguing for acceleration in H2 that then still will be slow.
Problem #1 – no inflection for Corlanor
Novartis estimates that the potentially eligible heart failure with reduced ejection fraction (HFrEF) patient population NYHA II-IV for Entresto is split 25% commercial, 65% Medicare Part D and 10% Medicaid/other. Whilst on the commercial side some formulary acceptance was achieved in 2015, PBMs have put tough pre-authorisation restrictions in place including prior failure on beta blockers and ACE inhibitors. For Medicare no reimbursement was anticipated for 2015 with National Drug Code (NDC) blocks in place. These NDC blocks result in significant out-of-pocket expenses for patients and even after formulary placement co-pays may represent costs up to 2-3x commercial co-pays (prior to falling into the Medicare doughnut hole) and normally these NDC blocks are removed after six (Entresto was launched in July 2015). This means in theory we should start to see an improvement in prescribing trends from January (gradual but improvement nevertheless).
FIGURE 4 Whilst Entresto's launch remains ahead of Corlanor's the lack of inflection is worrying
Source: IMS Health, Barclays Research
Amgen's Corlanor in chronic heart failure was launched in April 2015 (three months before the roll-out of Entresto) and the removal of NDC blocks should already have led to a pick-up in prescription trends as reimbursement expanded from commercial to the Medicare/Medicaid segments. Unfortunately this has not happened. Whilst significant prior authorisations and step edits are being imposed, we understand that the majority of Corlanor claims are getting approved with the last NDC blocks (Kaiser and United Health) removed by the end of 2015/early 2016. However despite access to >70% of covered lives, the Corlanor launch trajectory has remained linear since May 2015 and there has been no inflection point as NDC blocks have been removed. There is a different method of action and there is debate how applicable the European SHIFT trial is for the US market for Corlanor, but the lack of inflection is noticeable. At this point we do not understand why the removal of NDC blocks would provide an inflection point for Entresto prescriptions and not Corlanor prescriptions. Continued linear performance of prescriptions trends would not only be an issue for 2016 estimates but also the longer term outlook.
Problem #2 – will guideline updates boost Entresto in 2016?
Entrestro was approved by the FDA 7 July 2015, based on positive data from the PARADIGM-HF study (study was stopped early due to an overwhelming benefit with Entresto compared to an active control of ACE inhibitor enalapril dosed 10mg BID). Whilst the enalapril dose used in the trial is within the recommended dose range (per guidelines 10-20mg BID) and in-line with the two trials that led to inclusion of enalapril in HF guidelines (16.6mg and 18.4mg in the COnSEnSUS trial and SOLVD trials, respectively), the
trial did not use the maximum recommended dose (40mg daily as a single dose or in two divided doses).
FIGURE 5 2013 ACCF/AHA Guideline for the Management of Heart Failure (published June 2013)
Conditions for which there is evidence In all patients with a recent or remote history of MI or ACS and reduced EF, ACE
and/or general agreement that this
inhibitors should be used to prevent symptomatic HF and reduce mortality. In
procedure is useful and effective.
patients intolerant of ACE inhibitors, ARBs are appropriate unless contraindicated
Based on the presence of multiple
In all patients with a recent or remote history of MI or ACS, statins should be used to
randomized clinical trials.
prevent symptomatic HF and cardiovascular events In patients with structural cardiac abnormalities, including LV hypertrophy, in the absence of a history of MI or ACS, blood pressure should be controlled in accordance with clinical practice guidelines for hypertension to prevent symptomatic HF
ACE inhibitors should be used in all patients with a reduced EF to prevent
symptomatic HF, even if they do not have a history of MI
Based on the presence of a single
In all patients with a recent or remote history of MI or ACS and reduced EF, evidence-
randomized trial or nonrandomized
based beta blockers should be used to reduce mortality
Based on expert consensus
Beta blockers should be used in all patients with a reduced EF to prevent symptomatic
HF, even if they do not have a history of MI
Conditions for which there is conflicting To prevent sudden death, placement of an ICD is reasonable in patients with
evidence and/or a divergence of opinion asymptomatic ischemic cardiomyopathy who are at least 40 days post-MI, have an LVEF about the usefulness/efficacy of
of 30% or less, are on appropriate medical therapy, and have reasonable expectation of
performing the procedure
survival with a good functional status for more than 1 year
Weight of evidence/opinion is in favor of usefulness/ efficacy
Based on the presence of a single randomized trial or nonrandomized studies
Conditions for which there is evidence Nondihydropyridine calcium channel blockers with negative inotropic effects may be
and/or general agreement that the
harmful in asymptomatic patients with low LVEF and no symptoms of HF after MI
procedure is not useful/effective and in some cases may be harmful
Based on expert consensus
Source: Barclays Research, ACCF/AHA Guidelines; LOE – "Level Of Evidence"
The ACCF/AHA treatment guidelines for the management of heart failure classify the level of agreement on whether a medicine or procedure should be used and the level of evidence to support the recommendation. The use of ACE inhibitors such as enalapril for the treatment of patients with symptomatic heart failure whether they have a history of myocardial infarction or not is given the highest Class 1A recommendation in the guidelines. We believe that the ACCF/AHA treatment guidelines for the management of heart failure could be updated in 2016 to include treatment with Entresto based on the PARADIGM-HF trial data. However whilst Entresto could be potentially given a Class 1A / Class 1B recommendation, it is unlikely that the use of ACE inhibitors will be entirely demoted in the guidelines from a Class 1A recommendation. As an example Brilinta demonstrated a 16% reduction in the risk of cardiovascular death, non-fatal myocardial infarction and stroke in secondary prevention acute coronary syndromes patients compared to clopidogrel (a treatment benefit not dissimilar to that seen with Entresto over enalapril) yet the ACCF/AHA treatment guidelines for the management of acute coronary syndromes (updated October 2014) equally recommended clopidogrel and Brilinta at a Class 1B level but accompanied by a Class2a LOE B guideline that "it is reasonable to choose Brilinta over clopidogrel" in patients with NSTE-ACS treated with an early invasive, ischemia-guided and/or coronary stenting strategy.
Therefore in our view, Entresto is likely to continue to be impacted by tough prior-authorisation restrictions put in place by PBMs and patients will have to fail on ACE inhibitors ahead of starting treatment with Entresto.
Problem #3 – no help yet from heart failure with preserved ejection fraction
Entresto US revenues are currently annualising at $31m based on monthly IMS MIDAS data emphasising the difficult dynamics discussed above. Given the early stages of the roll-out, we analysed leading indicator data from AlphaImpactRx to hunt for clues as to what could be holding back the Entresto launch. These data suggest that the heart failure market is currently split 73% reduced ejection fraction and 27% preserved ejection fraction in terms of Total Written prescriptions (TWRx), which is somewhat different from the 50:50 split in terms of patients that Novartis has guided towards ahead of the PARAGON-HF study which is expected to complete May 2019. Whilst cardiologists make just over two thirds of New Written Prescription (NWRx) start decisions, TWRx's are split 56:44 between cardiologists and primary care physicians.
FIGURE 6 Entresto and Corlanor revenue progression has been slow
Source: IMS MIDAS
FIGURE 7 Entresto has captured a modest share of New Written Prescription starts in reduced ejection fraction heart failure patients
% HF market that is dynamic
Source: Barclays Research, AlphaImpactRx
This data suggests that there is no off-label use of Entresto in patients with preserved ejection fraction heart failure. As of November 2015, Entresto is capturing a 6.9% NWRx share of the reduced ejection fraction heart failure opportunity, with a TRWx share of just 2.4%. We believe that the primary care prescribing base is struggling the most with the
tough prior-authorisation restrictions put in place by PBMs, which is reflected in an NWRx share of 4.7%. We will continue to follow these data to see whether after capturing poorly controlled rEF heart failure patients, Entresto's NWRx share shows changes in dynamics. Whether the removal of NDC blocks and the potential for ACCF/AHA guideline changes will lead to a pickup in NWRx in 2016 remains to be seen. For now we are worried to see that even amongst specialists the new written prescription share is low (we would expect that specialists are more willing and able to get around pre-authorisation requests).
Cosentyx faring better (for now)
Cosentyx (psoriasis) is currently faring better than Entresto. Initial prescription trends may have been flattered by the loading dose of the product followed by a slight slowdown due to the monthly maintenance dosing (that is what our TWRx data suggests), and potentially there also is a small slowdown as the low hanging fruits of TNF/Stelara failures has been captured leaving the product to fight more for 1st line and methotrexate/Otezla failures. However, assuming the product continues to follow its linear launch trajectory that the IMS total prescriptions show, it is actually on track to make $1bn in 2016 revenues (our 2016 estimate v consensus $600m) in the US alone. IMS prescription volume suggests this market is expanding allowing for some share loss whilst still delivering overall growth.
FIGURE 8 New written prescription share - dermatologists
FIGURE 9 New written prescription share - dermatologists
FIGURE 10 Psoriasis market prescription trends - IMS
Source: IMS Health
Cosentyx' performance in Europe is harder to grasp for now (early days) but performance in countries like Germany is encouraging (33% value share).
FIGURE 11 Cosentyx v Stelara EU revenues
Source: IMS MIDAS
As US weekly prescriptions continue to deliver, confidence in Cosentyx estimates should increase in the next few months at least ahead of the launch of competitor ixekizumab (Lilly) in H1 2016. This launch of Lilly's competing anti-IL17 agent will provide an important focus point in the roll-out of Cosentyx, with additional share of voice providing an opportunity for the IL-17 class to make further inroads into the share of incumbents Stelara, Humira and Enbrel. However on the flip-side, an important focus will be how much market share ixekizumab captures from Cosentyx based on its efficacy and more convenient dosing profile.
FIGURE 12 Cosentyx and ixekizumab dosing schedule
Wk 10 Wk 11
Cosentyx 2x150mg 2x150mg 2x150mg 2x150mg
ixekizmb 2x80mg 1x80mg
Source: Barclays Research
Cosentyx is administered as two 150mg injections at the initiation of therapy, week 1, 2, 3, 4 and then monthly ie 8 individual injections in the first four weeks of treatment (10 in the first eight weeks). In the pivotal psoariasis trials at 12 weeks, Cosentyx demonstrated a PASI75 score (simplistically, 75% skin clearance) in 67-87% of patients and PASI90 score in 59% of patients. Lilly's ixekizumab is expected to be available in an autoinjector at launch, administered as two 80mg injections on treatment initiation followed by a single injection at week 2, 4, 6, 8, 10, 12 (four injections in the first four weeks and six in the first eight weeks) or a single injection at week 4, 8, 12 followed by a single 80mg injection every 4 or 12 weeks. Despite a lower injection burden, ixekizumab was able to demonstrate a PASI75 score in 87-90% of patients, a PASI90 score in 68-71% and a PASI100 in 35-41% of patients. The catch-22 is that just as the 2016/17 Entresto estimates may start to look shaky, confidence in Cosentyx might also take a hit as Lilly's product takes share.
Alcon – waiting for the growth acceleration plan
The loss of exclusivities within Alcon pharma has already impacted 2015 but an additional $300m in US revenues alone are exposed in 2016. On top of that Alcon's surgical division continues to struggle with a negative mix effect as patients are opting for mono-focal lenses instead of the higher priced multi-focal lenses (on top of that reimbursement systems
outside the US still don't really help). In general Alcon is facing an innovation problem that has driven a 2% decline in revenues (in constant currencies) in Q3, is likely to drive a further decline in Q4 and with the above mentioned loss of additional exclusivities means 2016 is also facing an uphill battle as headwinds will not annualise until late in the year. In response to this management has promised a ‘grow acceleration plan' (read restructuring plan?) to be announced with the FY results. As this mostly seems to be an innovation problem though we struggle to see how aggressively management would be able to drive growth in absence of new product launches (that will take time) unless products are in-licensed (Roche opting into ex-US Fovista rights in November clearly did not help). Here are the potential options we currently see none of which really deliver the quick fix the company may want given that 2016 is already a challenging year for the group given the Gleevec US patent expiry:
• Move Alcon pharma into Novartis pharma – there may be synergies to be had from the
Lucentis and Alcon pharma sales set-up/overlap but ultimately this would equate to watering the issue down by hiding it in the much larger Novartis pharma unit. Unfortunately unless the surgical division starts to grow significantly faster the impact on Alcon sales growth would be limited in the near term
• Dispose of contact lens solutions – the structural shift to daily contact lenses has had a
negative effect on lens solution revenues particularly as the EM growth has not been strong enough to offset this. Novartis could look to dispose of the solutions business but given its size (we estimate $556m in 2015 or 6% of Alcon) this is not enough to move the needle from a growth perspective. It would however slightly benefit the margin
• Cost efficiency program – whilst management has previously stated that the focus for
Alcon must be on the top-line and not the margin all bets may be off given things have not gone according to plan. Given that Alcon seems to be facing an innovation problem cuts to R&D seems unlikely in our view so efficiency gains would be limited to COGS and SG&A. An efficiency program is possible but with headwinds annualising in H2 we suspect management may take a watchful waiting approach before implementing such a program
Overall whilst management has options, it seems unlikely they will move the needle drastically or quickly and impacts in 2016 are likely going to be limited.
News flow – not enough in the tank
2016 is an execution year (Gleevec erosion v new oncology products acquired from GSK v Entresto and Cosentyx launch). What 2016 isn't really is a pipeline year. Overall there are only few items that we believe could cause some excitement (Tasigna treatment free remission data, LEE011, Tekturna ATMOSPHERE, serelaxin RELAX-AHF2) but there is enough controversy around each one of those items for the execution risk to remain in the driving seat. What % of Tasigna patients reaches sustained MR4.5 over 2 years and how does this stack up against Gleevec generics and tolerability being the main driver of switches in the CML market? Will Pfizer convert the accelerated Ibrance approval into full approval prior to LEE011 filing and will Lilly steal the show with abemaciclib (breakthrough status)? Would ATMOSPHERE overcome the Tasigna renal safety concerns? Who would pay for serelaxin (ER product)? Novartis' CEO is probably right that the company's early pipeline is not appreciated enough but this pipeline keeps moving out a year every year which means the near term challenges are a bigger concern for now.
FIGURE 13 Novartis near-term news flow
PKC412 filing in AML
Event driven pIII trial so pushed into 2016
PKC412 filing in aggressive systemic
Filing has shifted to 2016 to allow longer follow-up time for the pivotal
Afinitor approval in advanced non-
Filed Q3 2015 in US, Japan and EU
functional carcinoid tumors
Signifor filing in Crushing's disease
Patients with MR4.5 with >2 yr of Tasigna and 1yr of sustained MR4.5
Tasigna treatment free remission filing
High discontinued treatment and were monitored for 1 year
LEE011+letrozole filing in HR+/HER2-
Phase III study enrolled but no pII data and Pfizer gained accelerated
postmenopausal advanced breast cancer
approval for Ibrance and has survival data H1 2016. Lilly's abemaciclib has
1st line breast cancer (MONALEESA-2)
breakthrough status and does not require treatment holiday (data 2017)
Serelaxin RELAX-AHF2 trial in acute heart
Designed to replicate the mortality results from RELAX-AHF. Trial
significantly larger than RELAX-AHF. Not stopped at interim
ATMOSPHERE: Tekturna chronic heart
Impact of aliskiren on cardiovascular morbidity and mortality in patients
failure outcome study results
with acute and chronic congestive heart failure on top of standard therapy
In Aug. 2012, Novartis acquired rights from University of Pennsylvania to
CART-19 now identified as CTL019
BYM338 filing in sporadic inclusion body
Phase II data presented at American Neurological Association October
2013. Received FDA Breakthrough Therapy designation, Q3 2013
Ilaris/ACZ885 filing in hereditary periodic
Registration trial FPFV June 2014
Fovista (OAP030A/E10030) filing in wet
Roche has opted in as of November 2015
Gilenya filing in chronic inflammatory
Arzerra CLL filing (relapsed)
Afinitor filing TSC seizures
Was meant to be 2017 but lower than expected event rate pushed filing
Afinitor filing DLBCL
out but now saying 2016 again
BKM120+fulvestrant filing in mBC ER+ AI
BELLE-2 data disappointing - Novartis press release said no benefit overall
but looking at subgroups
BKM120+fulvestrant filing in 3rd line mBC
Promacta/Revolade filing myelodysplastic
syndrome / AML associated
Tafilnar/Mekinist filing in V600+ NSCLC
Tafilnar/Mekinist filing in V600+ adjuvant
Phase III trial initiated 2014. Novartis has entered into a clinical
Zykadia/LDK378 ALK+ NSCLC post
collaboration with BMY to evaluate Zykadia, INC280 and EGF816 in
chemo, crizotininb naïve filing
combination with BMY's nivolumab in Phase I/II trials in NSCLC
Promacta/Revolade filing myelodysplastic
Gilenya pIII in chronic inflammatory
Ilaris/ACZ885 filing secondary prevention
Interim analyses mid 2015 and H2 2016
LCI699 filing in Cushing's
Study design changed from single arm to randomized double-blinded trial
KAE609 filing in malaria
CTL019 filing in DLBCL
Arzerra NHL (refractory) filing
Arzerra NHL (relapsed) filing
Cosentyx/AIN457 filing in non-
radiographic axial spondyloarthritis
EGF816 filing in solid tumours
INC280 filing in NSCLC
LEE011+tamoxifene+goserelin or NSAI+goserelin filing in HR+/HER2-
premenopausal advanced breast cancer 1st line (MONALEESA-7)
QVM149 asthma filing
Zykadia/LDK378 ALK+ NSCLC (brain
LEE011 filing in solid tumors
Source: Company data, Barclays Research
FIGURE 14 Novartis 4Q15 preview
Continuing ($m except per share data)
Marketing & sales
% of revenues
Research & development
% of revenues
% of revenues
Other income & expense
Core operating profit
Income from associate companies
Net financial income
Income before tax
NI attributable to Novartis shareholders 2,450
Average number of shares outstanding
Core EPS (basic)
Sales by division
Core EBIT by division
Source: Company data, Barclays Research
FIGURE 15 Novartis 4Q15 preview
Total Pharma sales
Source: Barclays Research, Company data
We, Michael Leuchten, Mark Purcell and Olivia Capra, hereby certify (1) that the views expressed in this research report accurately reflect our personal views about any or all of the subject securities or issuers referred to in this research report and (2) no part of our compensation was, is or will be directly or indirectly related to the specific recommendations or views expressed in this research report.
IMPORTANT DISCLOSURES CONTINUED
Barclays Research is a part of the Investment Bank of Barclays Bank PLC and its affiliates (collectively and each individually, "Barclays"). Where any companies are the subject of this research report, for current important disclosures regarding those companies please send a written request to:Barclays Research Compliance, 745 Seventh Avenue, 13th Floor, New York, NY 10019 or refer to http://publicresearch.barclays.com or call 212-526-1072.
The analysts responsible for preparing this research report have received compensation based upon various factors including the firm's totalrevenues, a portion of which is generated by investment banking activities.
Research analysts employed outside the US by affiliates of Barclays Capital Inc. are not registered/qualified as research analysts with FINRA. Suchnon-US research analysts may not be associated persons of Barclays Capital Inc., which is a FINRA member, and therefore may not be subject to FINRA Rule 2241 restrictions on communications with a subject company, public appearances and trading securities held by a research analyst'saccount.
Analysts regularly conduct site visits to view the material operations of covered companies, but Barclays policy prohibits them from accepting payment or reimbursement by any covered company of their travel expenses for such visits.
In order to access Barclays Statement regarding Research Dissemination Policies and Procedures, please refer tohttp://publicresearch.barcap.com/static/S_ResearchDissemination.html. In order to access Barclays Research Conflict Management PolicyStatement, please refer to: http://publicresearch.barcap.com/static/S_ConflictManagement.html.
The Investment Bank's Research Department produces various types of research including, but not limited to, fundamental analysis, equity-linked analysis, quantitative analysis, and trade ideas. Recommendations contained in one type of research product may differ from recommendations contained in other types of research, whether as a result of differing time horizons, methodologies, or otherwise.
Primary Stocks (Ticker, Date, Price)
(NOVN.VX, 13-Jan-2016, CHF 82.85), Underweight/Neutral, A/C/D/E/J/K/L/M/N
Barclays Bank PLC and/or an affiliate has been lead manager or co-lead manager of a publicly disclosed offer of securities of the issuer in the
previous 12 months.
An employee of Barclays Bank PLC and/or an affiliate is a director of this issuer.
Barclays Bank PLC and/or an affiliate is a market-maker in equity securities issued by this issuer.
Barclays Bank PLC and/or an affiliate has received compensation for investment banking services from this issuer in the past 12 months.
Barclays Bank PLC and/or an affiliate expects to receive or intends to seek compensation for investment banking services from this issuer
within the next 3 months.
Barclays Bank PLC and/or an affiliate beneficially owned 1% or more of a class of equity securities of the issuer as of the end of the month prior
to the research report's issuance.
One of the analysts on the coverage team (or a member of his or her household) owns shares of the common stock of this issuer.
This issuer beneficially owns 5% or more of any class of common equity securities of Barclays PLC.
Barclays Bank PLC and/or an affiliate has a significant financial interest in the securities of this issuer.
Barclays Bank PLC and/or an affiliate is a liquidity provider and/or trades regularly in the securities of this issuer and/or in any related
Barclays Bank PLC and/or an affiliate has received non-investment banking related compensation (including compensation for brokerage
services, if applicable) from this issuer within the past 12 months.
This issuer is, or during the past 12 months has been, an investment banking client of Barclays Bank PLC and/or an affiliate.
This issuer is, or during the past 12 months has been, a non-investment banking client (securities related services) of Barclays Bank PLC
and/or an affiliate.
This issuer is, or during the past 12 months has been, a non-investment banking client (non-securities related services) of Barclays Bank PLC
and/or an affiliate.
Barclays Capital Inc., through Barclays Market Makers, is a Designated Market Maker in this issuer's stock, which is listed on the New York
Stock Exchange. At any given time, its associated Designated Market Maker may have "long" or "short" inventory position in the stock; and its
associated Designated Market Maker may be on the opposite side of orders executed on the floor of the New York Stock Exchange in the stock.
A partner, director or officer of Barclays Capital Canada Inc. has, during the preceding 12 months, provided services to the subject company for
remuneration, other than normal course investment advisory or trade execution services.
Barclays Bank PLC and/or an affiliate is a Corporate Broker to this issuer.
Barclays Capital Canada Inc. and/or an affiliate has received compensation for investment banking services from this issuer in the past 12
IMPORTANT DISCLOSURES CONTINUED
Barclays Capital Canada Inc. is a market-maker in an equity or equity related security issued by this issuer.
Barclays Bank PLC and/or an affiliate is providing equity advisory services to this issuer.
The equity securities of this Canadian issuer include subordinate voting restricted shares.
The equity securities of this Canadian issuer include non-voting restricted shares.
Barclays Bank PLC and/or an affiliate should be assumed to be an actual beneficial owner of 1% or more of all the securities (including debt
securities) of this issuer as of the end of the month prior to the research report's issuance.
Master limited partnerships (MLPs) are pass-through entities structured as publicly listed partnerships. For tax purposes, distributions to MLPunit holders may be treated as a return of principal. Investors should consult their own tax advisors before investing in MLP units.
Guide to the Barclays Fundamental Equity Research Rating System:
Our coverage analysts use a relative rating system in which they rate stocks as Overweight, Equal Weight or Underweight (see definitions below) relative to other companies covered by the analyst or a team of analysts that are deemed to be in the same industry (the "industry coverage universe").
In addition to the stock rating, we provide industry views which rate the outlook for the industry coverage universe as Positive, Neutral or Negative (see definitions below). A rating system using terms such as buy, hold and sell is not the equivalent of our rating system. Investors should carefully read the entire research report including the definitions of all ratings and not infer its contents from ratings alone.
- The stock is expected to outperform the unweighted expected total return of the industry coverage universe over a 12-month
- The stock is expected to perform in line with the unweighted expected total return of the industry coverage universe over a 12-
month investment horizon.
- The stock is expected to underperform the unweighted expected total return of the industry coverage universe over a 12-month
- The rating and target price have been suspended temporarily due to market events that made coverage impracticable or to
comply with applicable regulations and/or firm policies in certain circumstances including where the Investment Bank of Barclays Bank PLC is
acting in an advisory capacity in a merger or strategic transaction involving the company.
- industry coverage universe fundamentals/valuations are improving.
- industry coverage universe fundamentals/valuations are steady, neither improving nor deteriorating.
- industry coverage universe fundamentals/valuations are deteriorating.
Below is the list of companies that constitute the "industry coverage universe":
Almirall SA (ALM.MC)
Bayer AG (BAYGn.DE)
H Lundbeck A/S (LUN.CO)
Hikma Pharmaceuticals (HIK.L)
Merck KGaA (MRCG.DE)
Novo Nordisk (NOVOb.CO)
Distribution of Ratings:
Barclays Equity Research has 2829 companies under coverage.
41% have been assigned an Overweight rating which, for purposes of mandatory regulatory disclosures, is classified as a Buy rating; 50% of companies with this rating are investment banking clients of the Firm.
39% have been assigned an Equal Weight rating which, for purposes of mandatory regulatory disclosures, is classified as a Hold rating; 43% of companies with this rating are investment banking clients of the Firm.
16% have been assigned an Underweight rating which, for purposes of mandatory regulatory disclosures, is classified as a Sell rating; 37% of companies with this rating are investment banking clients of the Firm.
Guide to the Barclays Research Price Target:
Each analyst has a single price target on the stocks that they cover. The price target represents that analyst's expectation of where the stock will trade in the next 12 months. Upside/downside scenarios, where provided, represent potential upside/potential downside to each analyst's pricetarget over the same 12-month period.
Barclays Equity Research's "Top Picks" represent the single best alpha-generating investment idea within each industry (as defined by the relevant
IMPORTANT DISCLOSURES CONTINUED
"industry coverage universe"), taken from among the Overweight-rated stocks within that industry. Barclays Equity Research publishes global and
regional "Top Picks" reports every quarter and analysts may also publish intra-quarter changes to their Top Picks, as necessary. While analysts
may highlight other Overweight-rated stocks in their published research in addition to their Top Pick, there can only be one "Top Pick" for each
industry. To view the current list of Top Picks, go to the Top Picks
page on Barclays Live (https://live.barcap.com/go/keyword/TopPicksGlobal).
To see a list of companies that comprise a particular industry coverage universe, please go to http://publicresearch.barclays.com.
Barclays legal entities involved in publishing research:
Barclays Bank PLC (Barclays, UK)
Barclays Capital Inc. (BCI, US)
Barclays Securities Japan Limited (BSJL, Japan)
Barclays Bank PLC, Tokyo branch (Barclays Bank, Japan)
Barclays Bank PLC, Hong Kong branch (Barclays Bank, Hong Kong)
Barclays Capital Canada Inc. (BCCI, Canada)
Absa Bank Limited (Absa, South Africa)
Barclays Bank Mexico, S.A. (BBMX, Mexico)
Barclays Capital Securities Taiwan Limited (BCSTW, Taiwan)
Barclays Capital Securities Limited (BCSL, South Korea)
Barclays Securities (India) Private Limited (BSIPL, India)
Barclays Bank PLC, India branch (Barclays Bank, India)
Barclays Bank PLC, Singapore branch (Barclays Bank, Singapore)
Barclays Bank PLC, Australia branch (Barclays Bank, Australia)
IMPORTANT DISCLOSURES CONTINUED
Novartis (NOVN VX / NOVN.VX)
CHF 82.85 (13-Jan-2016)
Rating and Price Target Chart - CHF (as of 13-Jan-2016)
Adjusted Price Target
Jan- 2016 18-Jul-2013
Source: Thomson Reuters, Barclays Research
Historical stock prices and price targets may have been adjusted for stock splits and dividends.
Source: IDC, Barclays Research
Barclays Bank PLC and/or an affiliate has been lead manager or co-lead manager of a publicly disclosed offer of securities of Novartis in the
previous 12 months.
Barclays Bank PLC and/or an affiliate is a market-maker in equity securities issued by Novartis.
Barclays Bank PLC and/or an affiliate has received compensation for investment banking services from Novartis in the past 12 months.
Barclays Bank PLC and/or an affiliate expects to receive or intends to seek compensation for investment banking services from Novartis within
the next 3 months.
Barclays Bank PLC and/or an affiliate is a liquidity provider and/or trades regularly in the securities by Novartis and/or in any related
Barclays Bank PLC and/or an affiliate has received non-investment banking related compensation (including compensation for brokerage
services, if applicable) from Novartis within the past 12 months.
Novartis is, or during the past 12 months has been, an investment banking client of Barclays Bank PLC and/or an affiliate.
Novartis is, or during the past 12 months has been, a non-investment banking client (securities related services) of Barclays Bank PLC and/or
Novartis is, or during the past 12 months has been, a non-investment banking client (non-securities related services) of Barclays Bank PLC
and/or an affiliate.
We value Novartis through a DCF valuation assuming a risk-free derived from the yield curve, an equity risk premium of
5%, an asset beta of 0.9, pre-tax cost of debt based on CDS spreads and a target debt ratio of 10%. These assumptions result in a dynamic cost
of capital and our price target of CHF85.
Risks which May Impede the Achievement of the Barclays Research Valuation and Price Target:
Risks include: net cost savings and further
convincing clinical data on the upside, Entresto lack of commercial success and less cost control on the downside. Sector risks include further
healthcare reform efforts in the US/EU, more payor pressure, as well as further regulatory and pipeline set-backs.
This publication has been produced by the Investment Bank of Barclays Bank PLC and/or one or more of its affiliates (collectively and each individually,"Barclays"). It has been distributed by one or more Barclays legal entities that are a part of the Investment Bank as provided below. It is provided to our clientsfor information purposes only, and Barclays makes no express or implied warranties, and expressly disclaims all warranties of merchantability or fitness for aparticular purpose or use with respect to any data included in this publication. Barclays will not treat unauthorized recipients of this report as its clients andaccepts no liability for use by them of the contents which may not be suitable for their personal use. Prices shown are indicative and Barclays is not offeringto buy or sel or soliciting offers to buy or sel any financial instrument.
Without limiting any of the foregoing and to the extent permitted by law, in no event shall Barclays, nor any affiliate, nor any of their respective officers,directors, partners, or employees have any liability for (a) any special, punitive, indirect, or consequential damages; or (b) any lost profits, lost revenue, loss ofanticipated savings or loss of opportunity or other financial loss, even if notified of the possibility of such damages, arising from any use of this publication orits contents.
Other than disclosures relating to Barclays, the information contained in this publication has been obtained from sources that Barclays Research believes tobe reliable, but Barclays does not represent or warrant that it is accurate or complete. Barclays is not responsible for, and makes no warranties whatsoever asto, the content of any third-party web site accessed via a hyperlink in this publication and such information is not incorporated by reference.
The views in this publication are those of the author(s) and are subject to change, and Barclays has no obligation to update its opinions or the information inthis publication. If this publication contains recommendations, those recommendations reflect solely and exclusively those of the authoring analyst(s), andsuch opinions were prepared independently of any other interests, including those of Barclays and/or its affiliates. This publication does not constitutepersonal investment advice or take into account the individual financial circumstances or objectives of the clients who receive it. The securities discussedherein may not be suitable for all investors. Barclays recommends that investors independently evaluate each issuer, security or instrument discussed hereinand consult any independent advisors they believe necessary. The value of and income from any investment may fluctuate from day to day as a result ofchanges in relevant economic markets (including changes in market liquidity). The information herein is not intended to predict actual results, which maydiffer substantially from those reflected. Past performance is not necessarily indicative of future results.
This document is being distributed (1) only by or with the approval of an authorised person (Barclays Bank PLC) or (2) to, and is directed at (a) persons inthe United Kingdom having professional experience in matters relating to investments and who fall within the definition of "investment professionals" inArticle 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"); or (b) high net worth companies,unincorporated associations and partnerships and trustees of high value trusts as described in Article 49(2) of the Order; or (c) other persons to whom itmay otherwise lawfully be communicated (all such persons being "Relevant Persons"). Any investment or investment activity to which this communicationrelates is only available to and will only be engaged in with Relevant Persons. Any other persons who receive this communication should not rely on or actupon it. Barclays Bank PLC is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the PrudentialRegulation Authority and is a member of the London Stock Exchange.
The Investment Bank of Barclays Bank PLC undertakes U.S. securities business in the name of its wholly owned subsidiary Barclays Capital Inc., a FINRA andSIPC member. Barclays Capital Inc., a U.S. registered broker/dealer, is distributing this material in the United States and, in connection therewith acceptsresponsibility for its contents. Any U.S. person wishing to effect a transaction in any security discussed herein should do so only by contacting arepresentative of Barclays Capital Inc. in the U.S. at 745 Seventh Avenue, New York, New York 10019.
Non-U.S. persons should contact and execute transactions through a Barclays Bank PLC branch or affiliate in their home jurisdiction unless local regulationspermit otherwise.
Barclays Bank PLC, Paris Branch (registered in France under Paris RCS number 381 066 281) is regulated by the Autorité des marchés financiers and theAutorité de contrôle prudentiel. Registered office 34/36 Avenue de Friedland 75008 Paris.
This material is distributed in Canada by Barclays Capital Canada Inc., a registered investment dealer, a Dealer Member of IIROC (www.iiroc.ca), and aMember of the Canadian Investor Protection Fund (CIPF).
Subject to the conditions of this publication as set out above, the Corporate & Investment Banking Division of Absa Bank Limited, an authorised financialservices provider (Registration No.: 1986/004794/06. Registered Credit Provider Reg No NCRCP7), is distributing this material in South Africa. Absa BankLimited is regulated by the South African Reserve Bank. This publication is not, nor is it intended to be, advice as defined and/or contemplated in the (SouthAfrican) Financial Advisory and Intermediary Services Act, 37 of 2002, or any other financial, investment, trading, tax, legal, accounting, retirement, actuarialor other professional advice or service whatsoever. Any South African person or entity wishing to effect a transaction in any security discussed herein shoulddo so only by contacting a representative of the Corporate & Investment Banking Division of Absa Bank Limited in South Africa, 15 Alice Lane, Sandton,Johannesburg, Gauteng 2196. Absa Bank Limited is a member of the Barclays group.
In Japan, foreign exchange research reports are prepared and distributed by Barclays Bank PLC Tokyo Branch. Other research reports are distributed toinstitutional investors in Japan by Barclays Securities Japan Limited. Barclays Securities Japan Limited is a joint-stock company incorporated in Japan withregistered office of 6-10-1 Roppongi, Minato-ku, Tokyo 106-6131, Japan. It is a subsidiary of Barclays Bank PLC and a registered financial instruments firmregulated by the Financial Services Agency of Japan. Registered Number: Kanto Zaimukyokucho (kinsho) No. 143.
Barclays Bank PLC, Hong Kong Branch is distributing this material in Hong Kong as an authorised institution regulated by the Hong Kong MonetaryAuthority. Registered Office: 41/F, Cheung Kong Center, 2 Queen's Road Central, Hong Kong.
Information on securities/instruments that trade in Taiwan or written by a Taiwan-based research analyst is distributed by Barclays Capital SecuritiesTaiwan Limited to its clients. The material on securities/instruments not traded in Taiwan is not to be construed as 'recommendation' in Taiwan. BarclaysCapital Securities Taiwan Limited does not accept orders from clients to trade in such securities. This material may not be distributed to the public media orused by the public media without prior written consent of Barclays.
This material is distributed in South Korea by Barclays Capital Securities Limited, Seoul Branch.
All Indian securities-related research and other equity research produced by the Investment Bank are distributed in India by Barclays Securities (India) PrivateLimited (BSIPL). BSIPL is a company incorporated under the Companies Act, 1956 having CIN U67120MH2006PTC161063. BSIPL is registered andregulated by the Securities and Exchange Board of India (SEBI) as a Research Analyst: INH000001519; Portfolio Manager INP000002585; StockBroker/Trading and Clearing Member: National Stock Exchange of India Limited (NSE) Capital Market INB231292732, NSE Futures & OptionsINF231292732, NSE Currency derivatives INE231450334, Bombay Stock Exchange Limited (BSE) Capital Market INB011292738, BSE Futures & OptionsINF011292738; Merchant Banker: INM000011195; Depository Participant (DP) with the National Securities & Depositories Limited (NSDL): DP ID: IN-DP-NSDL-299-2008; Investment Adviser: INA000000391. The registered office of BSIPL is at 208, Ceejay House, Shivsagar Estate, Dr. A. Besant Road, Worli,Mumbai – 400 018, India. Telephone No: +91 2267196000. Fax number: +91 22 67196100. Any other reports produced by the Investment Bank are
distributed in India by Barclays Bank PLC, India Branch, an associate of BSIPL in India that is registered with Reserve Bank of India (RBI) as a BankingCompany under the provisions of The Banking Regulation Act, 1949 (Regn No BOM43) and registered with SEBI as Merchant Banker (Regn NoINM000002129) and also as Banker to the Issue (Regn No INBI00000950). Barclays Investments and Loans (India) Limited, registered with RBI as NonBanking Financial Company (Regn No RBI CoR-07-00258), and Barclays Wealth Trustees (India) Private Limited, registered with Registrar of Companies(CIN U93000MH2008PTC188438), are associates of BSIPL in India that are not authorised to distribute any reports produced by the Investment Bank.
Barclays Bank PLC Frankfurt Branch distributes this material in Germany under the supervision of Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin).
This material is distributed in Malaysia by Barclays Capital Markets Malaysia Sdn Bhd.
This material is distributed in Brazil by Banco Barclays S.A.
This material is distributed in Mexico by Barclays Bank Mexico, S.A.
Barclays Bank PLC in the Dubai International Financial Centre (Registered No. 0060) is regulated by the Dubai Financial Services Authority (DFSA). Principalplace of business in the Dubai International Financial Centre: The Gate Village, Building 4, Level 4, PO Box 506504, Dubai, United Arab Emirates. BarclaysBank PLC-DIFC Branch, may only undertake the financial services activities that fall within the scope of its existing DFSA licence. Related financial products orservices are only available to Professional Clients, as defined by the Dubai Financial Services Authority.
Barclays Bank PLC in the UAE is regulated by the Central Bank of the UAE and is licensed to conduct business activities as a branch of a commercial bankincorporated outside the UAE in Dubai (Licence No.: 13/1844/2008, Registered Office: Building No. 6, Burj Dubai Business Hub, Sheikh Zayed Road, DubaiCity) and Abu Dhabi (Licence No.: 13/952/2008, Registered Office: Al Jazira Towers, Hamdan Street, PO Box 2734, Abu Dhabi).
Barclays Bank PLC in the Qatar Financial Centre (Registered No. 00018) is authorised by the Qatar Financial Centre Regulatory Authority (QFCRA). BarclaysBank PLC-QFC Branch may only undertake the regulated activities that fall within the scope of its existing QFCRA licence. Principal place of business in Qatar:Qatar Financial Centre, Office 1002, 10th Floor, QFC Tower, Diplomatic Area, West Bay, PO Box 15891, Doha, Qatar. Related financial products or servicesare only available to Business Customers as defined by the Qatar Financial Centre Regulatory Authority.
This material is distributed in the UAE (including the Dubai International Financial Centre) and Qatar by Barclays Bank PLC.
This material is not intended for investors who are not Qualified Investors according to the laws of the Russian Federation as it might contain informationabout or description of the features of financial instruments not admitted for public offering and/or circulation in the Russian Federation and thus noteligible for non-Qualified Investors. If you are not a Qualified Investor according to the laws of the Russian Federation, please dispose of any copy of thismaterial in your possession.
This material is distributed in Singapore by the Singapore branch of Barclays Bank PLC, a bank licensed in Singapore by the Monetary Authority of Singapore.
For matters in connection with this report, recipients in Singapore may contact the Singapore branch of Barclays Bank PLC, whose registered address is 10Marina Boulevard, #23-01 Marina Bay Financial Centre Tower 2, Singapore 018983.
Barclays Bank PLC, Australia Branch (ARBN 062 449 585, AFSL 246617) is distributing this material in Australia. It is directed at 'wholesale clients' as definedby Australian Corporations Act 2001.
IRS Circular 230 Prepared Materials Disclaimer: Barclays does not provide tax advice and nothing contained herein should be construed to be tax advice.
Please be advised that any discussion of U.S. tax matters contained herein (including any attachments) (i) is not intended or written to be used, and cannotbe used, by you for the purpose of avoiding U.S. tax-related penalties; and (ii) was written to support the promotion or marketing of the transactions or othermatters addressed herein. Accordingly, you should seek advice based on your particular circumstances from an independent tax advisor.
Copyright Barclays Bank PLC (2016). All rights reserved. No part of this publication may be reproduced or redistributed in any manner without the priorwritten permission of Barclays. Barclays Bank PLC is registered in England No. 1026167. Registered office 1 Churchill Place, London, E14 5HP. Additionalinformation regarding this publication wil be furnished upon request.
TB treatment Multi-arm multi-stage trial to identify regimens to include in a phase III trial for shorter treatment of tuberculosis The PanACEA consortium aims to control. A number of interim analyses are The remaining 4 studies that were initially performed during the study to identify shorten TB treatment and consists of
Full-mouth disinfection: another choice for periodontal therapy Artículo extraído de la revista RAOA, Revista de la Asociación Odontológica Argentina, Vol. 97 – Nº4 – Agosto/Septiembre de 2009 Resumen El raspaje radicular realizado por sectores ha mostrado mejorar el cuadro de la patología gingivo-periodontal. Este insume varias sesiones y determinado tiempo de tratamiento.